| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5844997 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2012 | 6 Pages |
Abstract
⺠Much work remains in identifying a pharmacotherapy for METH dependence. ⺠Compounds that increase ACh may attenuate subjective effects produced by METH. ⺠The effects of rivastigmine were evaluated after METH administration in the lab. ⺠Rivastigmine significantly attenuated “Likely to Use METH”. ⺠Cholinesterase inhibitors warrant consideration as treatments for METH dependence.
Keywords
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
R. II, T.F. Newton, C.N. Haile, J.H. Yoon, C.S. Nerumalla, J.J. III, A. Aziziyeh,